† These authors contributed equally.
Background: The CO
Vulvar lichen sclerosus (VLS) (also named vulvar dystrophy) is characterized by atrophy of the vulva, hyperkeratosis, and scarring. VLS is an underrecognized and underdiagnosed disease [1], which occurs in all age groups. The mean age of onset is the mid to late 50 s, with approximately one-third of cases occurring in patients under 50 years old [2, 3]. Between 1991 and 2011, the incidence rate of VLS was 10.4 cases per 100,000 women-years and comparable incidence rates of VLS, ranging from 11.7 to 24.4 cases per 100,000 women-years, for patients between 50 and 59 years of age, have been found [2]. The aetiology of VLS is still mostly unknown. The principal symptom is itching, followed by burning and dyspareunia, in its most severe form, pallor and scarring of the skin of the anogenital region is present [4]. VLS causes a deterioration in the quality of life and if untreated, it is associated with a 2–6% lifetime risk of squamous cell carcinoma of the vulva [5].
Though potent steroids are considered the most effective treatment, robust
evidence concerning the superiority of potent steroid at least over calcineurin
inhibitors is still lacking the field of VLS [4]. And it may increase the risk of
malignant transformation [5]. The Fractional CO
This multi-centre, open-label, non-comparative study was conducted between
January 2017 and December 2018 at three centers. Women with biopsy-proven VLS who
were treated with a CO
The inclusion criteria included women older than 18 years, were diagnosed by biopsy with VLS, ever treatment or not, being symptomatic such as itching, burning, leukoderma (pallor), or hyperkeratosis. The exclusion criteria included women who had received medications during treatment cycles or during follow-up, and women who had acute genital infections or vulvar neoplasia.
The following characteristics were recorded for all patients: historical features, including age and menopausal status (premenopausal, postmenopausal with/without hormone therapy, duration of symptoms, and previous treatment). Objective parameters, including itching, burning, leukoderma (pallor), and hyperkeratosis, were considered to assess the clinical features and severity of the disease. Objective evaluation of each parameter was performed by the researchers using the visual analogue scale (VAS) to assess vulvar symptoms, where 0 indicated no symptoms and 10 indicated very severe symptoms, or the following 4-point scale was used: 0 = absence of symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The female sexual distress scale-revised (FSDS-R) was used to evaluate the patients’ sexual activity on a scale of 0 (not at all relevant) to 4 (extremely relevant) [9]. The family Dermatology Life Quality Index (DLQI) was used to evaluate the patients’ quality of life (QOL) on a scale of 0 (not at all) to 3 (very much) [10].
The treatment utilized a hand-held, forked probe that facilitated an accurate
focal length of the delivered laser beam. The laser was scanned in a boxlike
pattern to encompass the entirety of the involved vulva tissue. Settings for the
vulvar laser treatment were as follows: watts, 20; time, 1000 microseconds; and
width, 1000 micrometres. Treatment cycles included 3 laser treatment sessions at
monthly intervals. Follow-ups occurred at 3 months and 12 months posttreatment.
The CO
At the follow-up visits, the following features were recorded: subjective symptomatic response to treatment, objective clinical response to treatment, and adverse effects. The mean scores of the symptoms and disease indicators as well as the prevalence of each clinical parameter were evaluated.
ANOVA and Pearson correlation coefficient were used to determine the correlation
of the continuous scales with categorical and continuous variables respectively,
which was conducted using SPSS, version 20.0 (SPSS version 22.0; SPSS Inc,
Chicago, IL, USA). A p value
122 patients were enrolled in the study. The fractional CO
The mean duration of symptoms before presentation was 3.5 years (range, 1–10
years). A total of 64 (53.8%) patients were premenopausal, 35 (29.4%) patients
were postmenopausal and not using hormone therapy, and 20 (16.8%) patients were
postmenopausal using either topical or systemic hormone therapy.
Most of these patients had undergone previous
treatment for VLS, such as corticosteroids, herbs, hormones, and focused
ultrasound. Most of the patients had previously undergone more than one
therapeutic method (see Table 1). Symptoms were present in all patients at the
beginning of the study; the most frequent symptom was itching (105 patients,
88.2% of total), while 87 patients (73.1%) complained of burning. Leukoderma
(pallor) was the most frequent finding (92 patients, 77.3% of total).
Hyperkeratosis was found in 45 patients (37.8%). During the 12-month follow-up,
4 patients did not improve, and 115 patients improved the symptoms with different
degree. These 4 patients had a history of more than 3 years of VLS and undergone
treatments with corticosteroids, herbs and hormones. The mean baseline itching
score was 7.65 (1.07, range 0–10), and post-treatment, it was 4.52 (1.23, range
0–10) (3 months post-treatment) and 0.96 (1.49, range 0–10) (12 months
post-treatment), which indicated significant improvement (p
Number | Mean age | Mean duration | Previous topical therapies used | |||
(years) | (years) | |||||
Patients | Range (SD) | Range (SD) | Corticosteroids | Herbs | Hormones | Focused ultrasound |
n (%) | n (%) | n (%) | n (%) | |||
119 | 44.5 |
3.5 |
89 (74.8) | 78 (65.5) | 20 (16.8) | 27 (22.7) |
(27–72) | (1–10) |
Parameter | Baseline mean value | 3 months mean value | 12 months mean value | p value |
(SD) [range] | (SD) [range] | (SD) [range] | ||
Itching |
7.65 |
4.52 |
0.96 |
|
(0–10) | (0–10) | (0–10) | ||
Burning |
4.51 |
2.35 |
0.76 |
|
(0–10) | (0–8) | (0–4) | ||
Leukoderma |
2.45 |
1.26 |
0.5 |
|
(0–3) | (0–3) | (0–3) | ||
Hyperkeratosis |
1.24 |
0.53 |
0.34 |
0.016* |
(0–3) | (0–2) | (0–2) | ||
SD, Standard deviation. |
The mean baseline DLQL score was 14.24 (5.64, range 0–30), and post-treatment,
it was 8.7 (1.9, range 0–15) (3 months post-treatment), and 5.7 (2.3, range
0–10) (12 months post-treatment), which indicated significant improvement
(p
Parameter | Baseline mean value | 3 months mean value | 12 months mean value | p value |
(SD) [range] | (SD) [range] | (SD) [range] | ||
DLQL | 14.24 |
8.7 |
5.7 |
|
(0–30) | (0–15) | (0–10) | ||
FSDS | 15.48 |
12.51 |
7.87 |
0.031 |
(0–51) | (0–45) | (0–50) | 0.001* | |
*the score of 3 months and the baseline was 0.016, and the score of 12 moths and the baseline was 0.001. |
Our study found that itching, burning and leukoderma (pallor) were the most
common features of VLS, in accordance with similar studies, and that itching was
the most common symptom based on the VLS, mean score, also in accordance with
previous reports [11, 12]. The fractional CO
Most patients enrolled in previously published studies were postmenopausal women
[7, 8, 13, 14], however, most patients in our study were premenopausal women
(mean age 44.5
Lichen sclerosus was characterized by the creation of inflammation and
eventually severe scar tissue formation leading to shrinkage, or atrophy, of the
tissue. It was well known that topical corticosteroid (TCS) was an effective and
safe treatment for VLS [16]; however, even potent TCS cannot achieve complete
control of the disease in some VLS cases [17]. CO
The mechanism of the carbon dioxide action is that the laser absorbs light
energy through water molecules in the epidermis, leading to heat accumulation and
subsequent ablation of the epidermis and superficial dermis [20]. Fractional
CO
This study demonstrated that fractional CO
One strength of our study was the use of specific standardized questionnaires to evaluate patients’ quality of life and sexual function. We also added a subjective evaluation based on patients’ perception of VLS symptoms, however, there may be low intrarater reliability in scoring activity of VLS patients. Compared with other single-centre studies, the patients enrolled in our study were from three hospitals. However, the follow-up in our study was completed at 12 months post-treatment, which was relatively shorter than in previous studies. And the future studies should emphasize patient age and VLS-duration stratification with longer follow-up.
In conclusion, the fractional CO
XJW: Data acquisition, writing initial draft, and statistical analysis. YSC, LWW
and ZL: CO
All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board and Ethics Committee of Obstetrics and Gynecology Hospital of Fudan University (No: 2017-02).
We would like to express our gratitude to all the peer reviewers for their opinions and suggestions.
This work was supported by the Special Foundation Project of “Application of Laser in Gynecology and Obstetrics” of China Association Plastics and Aesthetics under Grant, grant Number: FRPR201601-02.
The authors declared no conflict of interest.